| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Paul N Goldwater | |
| P2860 | cites work | The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections | Q24623245 |
| Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I | Q24651553 | ||
| Isolation and characterization of a new T-even bacteriophage, CEV1, and determination of its potential to reduce Escherichia coli O157:H7 levels in sheep | Q28390402 | ||
| Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1 | Q33328717 | ||
| Inflammatory and immunological parameters in children with haemolytic uremic syndrome (HUS) and gastroenteritis-pathophysiological and diagnostic clues | Q33332698 | ||
| Shiga toxin-2 induces neutrophilia and neutrophil activation in a murine model of hemolytic uremic syndrome | Q33332898 | ||
| Escherichia coli 'O' group serology of a haemolytic uraemic syndrome (HUS) epidemic | Q33333740 | ||
| The management of VTEC O157 infection | Q33337746 | ||
| Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome | Q33340490 | ||
| Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome | Q33343017 | ||
| Escherichia coli 'O' group serological responses and clinical correlations in epidemic HUS patients | Q33343335 | ||
| Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis | Q33343861 | ||
| Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial | Q33349877 | ||
| Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease | Q33357336 | ||
| An outbreak of Escherichia coli O157 infection following exposure to a contaminated building | Q33357846 | ||
| Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. | Q33358728 | ||
| The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. 1985. | Q33359706 | ||
| Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion | Q33366604 | ||
| Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond | Q33369757 | ||
| Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh | Q33369800 | ||
| Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome | Q33373427 | ||
| Haemolytic anaemia after childhood Escherichia coli O 157 .H7 infection: are females at increased risk? | Q33389799 | ||
| Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome | Q33445938 | ||
| Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools | Q33475757 | ||
| Antibodies to lipopolysaccharide block adherence of Shiga toxin-producing Escherichia coli to human intestinal epithelial (Henle 407) cells | Q33501646 | ||
| New perspectives on the role of Escherichia coli O157:H7 and other enterohaemorrhagic E. coli serotypes in human disease | Q33504655 | ||
| Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. | Q33505061 | ||
| Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. | Q33889513 | ||
| Neutralization of Shiga toxins Stx1, Stx2c, and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose | Q34006601 | ||
| Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression | Q34009265 | ||
| Shiga toxin of enterohemorrhagic Escherichia coli type O157:H7 promotes intestinal colonization. | Q34667008 | ||
| Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants | Q34973928 | ||
| Bovine immune response to shiga-toxigenic Escherichia coli O157:H7 | Q35216120 | ||
| Production of secretory immunoglobulin A against Shiga toxin-binding subunits in mice by mucosal immunization | Q35550028 | ||
| Genetic medicine at the RNA level: modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing | Q35928212 | ||
| First-time isolation and characterization of a bacteriophage encoding the Shiga toxin 2c variant, which is globally spread in strains of Escherichia coli O157. | Q37624022 | ||
| Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues. | Q38315562 | ||
| Polyisobutylmethacrylate modifies glycolipid binding specificity of verotoxin 1 in thin-layer chromatogram overlay procedures | Q38329511 | ||
| 4-Aminopyrazolo[3,4-d]pyrimidine (4-APP) as a novel inhibitor of the RNA and DNA depurination induced by Shiga toxin 1 | Q39543360 | ||
| Analysis and genetic manipulation of Shigella virulence determinants for vaccine development | Q39649713 | ||
| Mutation of toxB and a truncated version of the efa-1 gene in Escherichia coli O157:H7 influences the expression and secretion of locus of enterocyte effacement-encoded proteins but not intestinal colonization in calves or sheep. | Q40014538 | ||
| Comparison of a Shiga Toxin Enzyme-Linked Immunosorbent Assay and Two Types of PCR for Detection of Shiga Toxin-Producing Escherichia coli in Human Stool Specimens | Q40133558 | ||
| Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture | Q40592342 | ||
| Protection against hemorrhagic colitis in an animal model by oral immunization with isogeneic rabbit enteropathogenic Escherichia coli attenuated by truncating intimin | Q41918883 | ||
| Description of a 111-kb pathogenicity island (PAI) encoding various virulence features in the enterohemorrhagic E. coli (EHEC) strain RW1374 (O103:H2) and detection of a similar PAI in other EHEC strains of serotype 0103:H2. | Q43169150 | ||
| Genetically modified Shiga toxin 2e (Stx2e) producing Escherichia coli is a vaccine candidate for porcine edema disease | Q43654014 | ||
| Delivery of heterologous protein antigens via hemolysin or autotransporter systems by an attenuated ler mutant of rabbit enteropathogenic Escherichia coli | Q44320998 | ||
| Cytotoxic Escherichia coli serotypes | Q44774240 | ||
| Refinement of a therapeutic Shiga toxin-binding probiotic for human trials | Q44873305 | ||
| Bovine colostrum ameliorates diarrhea in infection with diarrheagenic Escherichia coli, shiga toxin-producing E. Coli, and E. coli expressing intimin and hemolysin | Q45233298 | ||
| Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition | Q48093292 | ||
| Fecal prevalence of Escherichia coli O157, Salmonella, Listeria, and Bacteriophage Infecting E. coli O157:H7 in feedlot cattle in the Southern Plains region of the United States | Q50077106 | ||
| Immunization of mice with live oral vaccine based on a Salmonella enterica (sv Typhimurium) aroA strain expressing the Escherichia coli O111 O antigen | Q50126002 | ||
| Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. | Q50557922 | ||
| Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. | Q54105146 | ||
| Seasonal shedding of Escherichia coli O157:H7 in ruminants: a new hypothesis. | Q54449205 | ||
| Diversity of virulence patterns among shiga toxin-producing Escherichia coli from human clinical cases-need for more detailed diagnostics. | Q54486873 | ||
| The Shiga toxin 2 B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. | Q54502689 | ||
| Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2☆ | Q57563815 | ||
| P433 | issue | 4 | |
| P921 | main subject | Escherichia coli | Q25419 |
| enterohaemorrhagic Escherichia coli infection | Q1344603 | ||
| P304 | page(s) | 653-663 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome | |
| P478 | volume | 5 |
| Q33383255 | Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic syndrome pathology |
| Q41373102 | Development of a dual vaccine for prevention of Brucella abortus infection and Escherichia coli O157:H7 intestinal colonization |
| Q33387236 | Globotriaosyl ceramide receptor function - where membrane structure and pathology intersect |
| Q34394719 | Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection |
| Q64039312 | Management of STEC Gastroenteritis: Is There a Role for Probiotics? |
| Q50026293 | Oral immunization with attenuated Salmonella vaccine expressing Escherichia coli O157:H7 intimin gamma triggers both systemic and mucosal humoral immunity in mice. |
| Q35956792 | Structure-dependent pseudoreceptor intracellular traffic of adamantyl globotriaosyl ceramide mimics |
| Q33383031 | Treatment options for HUS secondary to Escherichia coli O157:H7. |
| Q35829561 | Type III Secretion-Dependent Sensitivity of Escherichia coli O157 to Specific Ketolides |
| Q50039335 | Vaccination of attenuated EIS-producing Salmonella induces protective immunity against enterohemorrhagic Escherichia coli in mice |
Search more.